



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

September 1, 2017

Saeed Motahari
President and Chief Executive Officer
Insys Therapeutics, Inc.
1333 S. Spectrum Blvd, Suite 100
Chandler, Arizona 85286

Re: Insys Therapeutics, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2016
Filed April 3, 2017
File No. 001-35902

Dear Mr. Motahari:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff.

Division of Corporation Finance
Office of Healthcare and
Insurance